...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Report Of Exempt Distribution.

"What is this exemption distribution?  another of DM loan to RVX , a Peter to pay Paul loan to keep RVX a float"

prob for dons hard earned wage - raping both companies simultaneously? Looks like this will go on until the end of this year when I believe most zen trials wrap up allowing them to possibly do a deal that helps rvx out - I'm expecting nothing right to & including rvx agm in June & continuing to the end of this year & most likely the first quarter of 2025 before anything happens - only thing we see is hepa extends the loan or Don & company pay it off & we wait. A year out possible two with this bag of fleas imo.

Share
New Message
Please login to post a reply